BST2/tetherin enhances entry of human cytomegalovirus

PLoS Pathogens

Volumn 7, Issue 11, 2011, Pages

  Viswanathan, Kasinath ^a   Smith, M Shane ^a   Malouli, Daniel ^a   Mansouri, Mandana ^a   Nelson, Jay A ^a   Früh, Klaus ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BST2 PROTEIN; INTERFERON; PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VIRUS PROTEIN; BST2 PROTEIN, HUMAN; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; LEUKOCYTE ANTIGEN;

ARTICLE; CELL DIFFERENTIATION; CELL MEMBRANE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EBOLA VIRUS; FIBROBLAST; GENE EXPRESSION; HERPES VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERFERON INDUCTION; MOLECULAR INTERACTION; MOLECULAR MECHANICS; MONOCYTE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; SUPERNATANT; VIRION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS PARTICLE; VIRUS RELEASE; CELL LINE; CELL STRAIN HEK293; GENE EXPRESSION REGULATION; GENETICS; HUMAN HERPESVIRUS 8; METABOLISM; PHYSIOLOGY; RNA INTERFERENCE; VIROLOGY;

EBOLA VIRUS; HUMAN HERPESVIRUS 5; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIGENS, CD; CELL LINE; CYTOMEGALOVIRUS; EBOLAVIRUS; GENE EXPRESSION REGULATION, VIRAL; GPI-LINKED PROTEINS; HEK293 CELLS; HERPESVIRUS 8, HUMAN; HIV-1; HUMANS; MONOCYTES; RNA INTERFERENCE; RNA, SMALL INTERFERING; VIRUS INTERNALIZATION; VIRUS RELEASE;

EID: 81755177797     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002332     Document Type: Article

References (45)

1. Emery VC, (2001) Investigation of CMV disease in immunocompromised patients. J Clin Pathol 54: 84-88.
2. Scholz M, Doerr HW, Cinat J, (2003) Human cytomegalovirus retinitis: pathogenicity, immune evasion and persistence. Trends Microbiol 11: 171-177.
3. Griffiths PD, Walter S, (2005) Cytomegalovirus. Curr Opin Infect Dis 18: 241-245.
4. Streblow DN, Orloff SL, Nelson JA, (2001) Do pathogens accelerate atherosclerosis. J Nutr 131: 2798S-2804S.
5. Soderberg-Naucler C, (2008) HCMV microinfections in inflammatory diseases and cancer. J Clin Virol 41: 218-223.
6. Sweet C, (1999) The pathogenicity of cytomegalovirus. FEMS Microbiol Rev 23: 457-482.
7. Compton T, (2004) Receptors and immune sensors: the complex entry path of human cytomegalovirus. Trends Cell Biol 14: 5-8.
8. Ryckman BJ, Jarvis MA, Drummond DD, Nelson JA, Johnson DC, (2006) Human Cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J Virol 80: 710-722.
9. Sinzger C, (2008) Entry route of HCMV into endothelial cells. J Clin Virol 41: 174-179.
10. Goto T, Kennel SJ, Abe M, Takishita M, Kosaka M, et al. (1994) A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 84: 1922-1930.
11. Blasius AL, Giurisato E, Cella M, Schreiber RD, Shaw AS, et al. (2006) Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation. J Immunol 177: 3260-3265.
12. Cao W, Bover L, Cho M, Wen X, Hanabuchi S, et al. (2009) Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med 206: 1603-1614.
13. Bartee E, McCormack A, Fruh K, (2006) Quantitative membrane proteomics reveals new cellular targets of viral immune modulators. PLoS Pathog 2: e107.
14. Mansouri M, Viswanathan K, Douglas JL, Hines J, Gustin J, et al. (2009) Molecular mechanism of BST2/Tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J Virol 83: 9672-9681.
15. Neil SJD, Zang T, Bieniasz PD, (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451: 425-430.
16. Damme NV, Goff D, Katsura C, Jorgenson RL, Mitchell R, et al. (2008) The interferon-Induced protein BST-2 restricts HIV-1 release and Is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3: 1-8.
17. Douglas JL, Viswanathan K, McCarroll MN, Gustin JK, Fruh K, et al. (2009) Vpu directs the degradation of the human Immunodeficiency virus restriction factor BST-2/Tetherin via a beta TrCP-dependent mechanism. J Virol 83: 7931-7947.
18. Schubert U, Anton LC, Bacik I, Cox JH, Bour S, et al. (1998) CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J Virol 72: 2280-2288.
19. Douglas JL, Gustin JK, Viswanathan K, Mansouri M, Moses AV, et al. (2010) The great escape: viral strategies to counter BST-2/Tetherin. PLoS Pathog 6: e1000913.
20. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J, (2009) Inhibition of Lassa and Marburg virus production by tetherin. J Virol 83: 2382-2385.
21. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P, (2009) Tetherin-mediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc Natl Acad Sci U S A 106: 2886-2891.
22. Jouvenet N, Neil SJD, Zhadina M, Zang T, Kratovac Z, et al. (2009) Broad-spectrum inhibition of Retroviral and Filoviral particle release by tetherin. J Virol 83: 1837-1844.
23. Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, et al. (2009) Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6: 54-67.
24. Arnaud F, Black S, Murphy L, Griffiths D, Neil SJ, et al. (2010) Interplay between Ovine bone marrow stromal cell antigen 2 (BST2)/Tetherin and endogenous retroviruses. J Virol 84: 4415-4425.
25. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, et al. (2003) Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4: 694-709.
26. Rollason R, Korolchuk V, Hamilton C, Schu P, Banting G, (2007) Clathrin-mediated endocytosis of a lipid-raftassociated protein is mediated through a dual tyrosine motif. J Cell Sci 120: 3850-3858.
27. Hinz A, Miguet N, Natrajan G, Usami Y, Yamanaka H, et al. (2010) Structural Basis of HIV-1 Tethering to Membranes by the BST-2/Tetherin Ectodomain. Cell Host Microbe 7: 1-10.
28. Bieniasz PD, (2009) The cell biology of HIV-1 virion genesis. Cell Host Microbe 5: 550-558.
29. Kalejta RF, (2008) Tegument proteins of human cytomegalovirus. Microbiol Mol Biol Rev 72: 249-265.
30. DeFilippis VR, Robinson B, Keck TM, Hansen SG, Nelson JA, et al. (2006) Interferon regulatory factor 3 is necessary for induction of antiviral genes during human cytomegalovirus infection. J Virol 80: 1032-1037.
31. Miller DM, Rahill BM, Boss JM, Lairmore MD, Durbin JE, et al. (1998) Human cytomegalovirus inhibits major histocompatibility complex class II expression by disruption of the Jak/Stat pathway. J Exp Med 187: 675-683.
32. Navarro L, Mowen K, Rodems S, Weaver B, Reich N, et al. (1998) Cytomegalovirus activates interferon immediate-early response gene expression and an interferon regulatory factor 3-containing interferon-stimulated response element-binding complex. Mol Cell Biol 18: 3796-3802.
33. Smith MS, Bentz GL, Alexander JS, Yurochko AD, (2004) Human cytomegalovirus induces monocyte differentiation and migration as a strategy for dissemination and persistence. J Virol 78: 4444-4453.
34. Soderberg-Naucler C, Fish KN, Nelson JA, (1997) Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 91: 119-126.
35. Ibanez CE, Schrier R, Ghazal P, Wiley C, Nelson JA, (1991) Human cytomegalovirus productively infects primary differentiated macrophages. J Virol 65: 6581-6588.
36. Turtinen LW, Seufzer BJ, (1994) Selective permissiveness of TPA differentiated THP-1 myelomonocytic cells for human cytomegalovirus strains AD169 and Towne. Microb Pathog 16: 373-378.
37. Gerna G, Percivalle E, Sarasini A, Baldanti F, Campanini G, et al. (2003) Rescue of human cytomegalovirus strain AD169 tropism for both leukocytes and human endothelial cells. J Gen Virol 84: 1431-1436.
38. Varnum SM, Streblow DN, Monroe ME, Smith P, Auberry KJ, et al. (2004) Identification of proteins in human cytomegalovirus(HCMV) particles: the HCMV proteome. J Virol 78: 10960-10966.
39. DeFilippis VR, Alvarado D, Sali T, Rothenburg S, Früh K, (2010) Human Cytomegalovirus Induces the Interferon Response via the DNA Sensor ZBP1. J Virol 84: 585-598.
40. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, et al. (2009) Tetherin Inhibits HIV-1 release by directly tethering virions to cells. Cell 139: 499-511.
41. Willcox BE, Thomas LM, Chapman TL, Heikema AP, West AP, et al. (2002) Crystal structure of LIR-2 (ILT4) at 1.8 Å: differences from LIR-1 (ILT2) in regions implicated in the binding of the Human Cytomegalovirus class I MHC homolog UL18. BMC Struct Biol 2: 6.
42. Ozaki S, Kosaka M, Wakatsuki S, Abe M, Koishihara Y, et al. (1997) Immunotherapy of Multiple Myeloma With a Monoclonal Antibody Directed Against a Plasma Cell-Specific Antigen, HM1.24. Blood 90: 3179-3186.
43. Michaelis M, Doerr HW, Cinatl J, (2009) The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia 11: 1-9.
44. Bresnahan WA, Hultman GE, Shenk T, (2000) Replication of wild-type and mutant human cytomegalovirus in life-extended human diploid fibroblasts. J Virol 74: 10816-10818.
45. Kalejta RF, (2003) Human cytomegalovirus pp71 stimulates cell cycle progression by inducing the proteasome-dependant degradation of the retinoblastoma family of tumor suppressors. Mol Cell Biol 23: 1885-1895.